{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-157303","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.087453+00:00","generated_at":"2026-05-18T08:43:51.025748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M","bullets":["Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.","Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.","Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.","Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.","First revenue quarter for VYKAT XR; financial close and review ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-157303","json":"https://secwatch.observer/filing/0001193125-25-157303.json","markdown":"https://secwatch.observer/filing/0001193125-25-157303.md","text":"https://secwatch.observer/filing/0001193125-25-157303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/0001193125-25-157303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525157303/d98442d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:43:51.025748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}